Future uncertain for Orphazyme CEO as firm sold
Although the plan is that the majority of Orphazyme’s 20 remaining employees will now work for the new owner, US-based Kempharm, it is not yet clear whether CEO Anders Vadsholt will join them, he tells MedWatch.
by christopher due karlsson, translated by catherine brett
Since the start of March, CEO Anders Vadsholt has guided listed biotech company Orphazyme through choppy waters, but it is far from certain that he will make the voyage across the Atlantic to join the firm’s new owners, Kempharm.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme didn't know buyer before negotiations began
For subscribers
Orphazyme sells entire business to US biotech company
For subscribers
.jpg&w=384&q=75)
